Review of solid-organ transplantation in HIV-infected patients

Transplantation

Volumn 75, Issue 4, 2003, Pages 425-429

  Roland, Michelle E ^a,b   Stock, Peter G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; CALCINEURIN INHIBITOR; CYCLOSPORIN; INTERLEUKIN 2; LAMIVUDINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NUCLEOSIDE ANALOG; RAPAMYCIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TACROLIMUS; TENOFOVIR; ZIDOVUDINE;

COMORBIDITY; CYTOMEGALOVIRUS; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOXICITY; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; HEPATITIS B; HERPES SIMPLEX VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER TRANSPLANTATION; OPPORTUNISTIC INFECTION; OUTCOMES RESEARCH; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK BENEFIT ANALYSIS; SURGICAL RISK; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; TRANSPLANTATION TOLERANCE; TREATMENT FAILURE; TREATMENT INDICATION; VIRUS REPLICATION;

HIV INFECTIONS; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LIVER FAILURE; LIVER TRANSPLANTATION; PATIENT SELECTION;

EID: 0037468496     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000046943.35335.18     Document Type: Review

References (47)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338(13): 853.
2. Halpern SD, Ubel PA, Caplan AL. Solid-organ transplantation in HIV-infected patients. N Engl J Med 2002; 347(4): 284.
3. Tzakis AG, Cooper MH, Dummer JS, et al. Transplantation in HIV+ patients. Transplantation 1990; 49(2): 354.
4. Schwarz A, Offermann G, Keller F, et al. The effect of cyclosporine on the progression of human immunodeficiency virus type 1 infection transmitted by transplantation: data on four cases and review of the literature. Transplantation 1993; 55(1): 95.
5. Jacobson SK, Calne RY, Wreghitt TG. Outcome of HIV infection in transplant patient on cyclosporin [letter]. Lancet 1991; 337(8744): 794.
6. Erice A, Rhame FS, Heussner RC, et al. Human immunodeficiency virus infection in patients with solid-organ transplants: report of five cases and review. Rev Infect Dis 1991; 13 (4): 537.
7. Ahuja TS, Zingman B, Glicklich D. Long-term survival in an HIV-infected renal transplant recipient. Am J Nephrol 1997; 17(5): 480.
8. Ragni MV, Bontempo FA, Lewis JH. Organ transplantation in HIV-positive patients with hemophilia [letter]. N Engl J Med 1990; 322(26): 1886.
9. Poli F, Scalamogna M, Pizzi C, et al. HIV infection in cadaveric renal allograft recipients in the North Italy Transplant Program. Transplantation 1989; 47(4): 724.
10. Roland MC, Ragni L, Rohal M, et al. Solid organ transplantation in HIV-infected recipients: forty-seven cases in the HAART-era. Presented at the XIV International AIDS Conference, Barcelona, Spain, July 7-12, 2002.
11. Prachalias AA, Pozniak A, Taylor C, et al. Liver transplantation in adults coinfected with HIV. Transplantation 2001; 72(10): 1684.
12. de Vera ME, Eghtesad B, Jain A, et al. Liver transplantation in patients co-infected with HIV and hepatitis C. Presented at the American Transplant Congress 2002, Washington, DC, April 25-May 1, 2002.
13. Department of Health and Human Services, Henry J. Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR Recomm Rep 1998; 47 (RR-5): 43.
14. Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. Jama 1998; 280(17): 1497.
15. Rao TK, Friedman EA, Nicastri AD. The types of renal disease in the acquired immunodeficiency syndrome. N Engl J Med 1987; 316(17): 1062.
16. Shahinian V, Rajaraman S, Borucki M, et al. Prevalence of HIV-associated nephropathy in autopsies of HIV-infected patients. Am J Kidney Dis 2000; 35(5): 884.
17. Perinbasekar S, Brod-Miller C, Pal S, et al. Predictors of survival in HIV-infected patients on hemodialysis. Am J Nephrol 1996; 16(4): 280.
18. Ahuja TS, Borucki M, Grady J. Highly active antiretroviral therapy improves survival of HIV-infected hemodialysis patients. Am J Kidney Dis 2000; 36(3): 574.
19. Ockenga J, Tillmann HL, Trautwein C, et al. Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value. J Hepatol 1997; 27(1): 18.
20. Colin JF, Cazals-Hatem D, Loriot MA, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999; 29(4): 1306.
21. Lesens O, Deschenes M, Steben M, et al. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. J Infect Dis 1999; 179(5): 1254.
22. Sulkowski MS, Thomas DL, Chaisson RE, et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. Jama 2000; 283(1): 74.
23. Puoti M, Gargiulo F, Roldan EQ, et al. Liver damage and kinetics of hepatitis C virus and human immunodeficiency virus replication during the early phases of combination antiretroviral treatment. J Infect Dis 2000; 181(6): 2033.
24. Bessesen M, Ives D, Condreay L, et al. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999; 28(5): 1032.
25. Carr A, Morey A, Mallon P, et al. Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia. Lancet 2001; 357(9266): 1412.
26. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32(3): 492.
27. Shearer GM, Clerici M. In vitro analysis of cell-mediated immunity: clinical relevance. Clin Chem 1994; 40 (11 Pt 2): 2162.
28. Groux H, Torpier G, Monte D, et al. Activation-induced death by apoptosis in CD4+ T cells from human immunodeficiency virus-infected asymptomatic individuals. J Exp Med 1992; 175(2): 331.
29. Calabrese LH, Lederman MM, Spritzler J, et al. Placebo-controlled trial of cyclosporin-A in HIV-1 disease: implications for solid organ transplantation. J Acquir Immune Defic Syndr 2002; 29(4): 356.
30. Andrieu JM, Even P, Venet A, et al. Effects of cyclosporin on T-cell subsets in human immunodeficiency virus disease. Clinical Immunology and Immunopathology 1988; 47(2): 181.
31. Rizzardi GP, Harari A, Capiluppi B, et al. Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J Clin Invest 2002; 109(5): 681.
32. Margolis D, Heredia A, Gaywee J, et al. Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity. J Acquir Immune Defic Syndr 1999; 21(5): 362.
33. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5(5): 512.
34. Perrillo R, Schiff E, Yoshida E, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32(1): 129.
35. Ying C, De Clercq E, Nicholson W, et al. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. J Viral Hepat 2000; 7(2): 161.
36. Kosuge H. HHV-6, 7 and their related diseases. J Dermatol Sci 2000; 22(3): 205.
37. Cattani P, Nanni G, Graffeo R, et al. Pretransplantation human herpes virus 8 seropositivity as a risk factor for Kaposi's sarcoma in kidney transplant recipients. Transplantation Proceedings 2000; 32(3): 526.
38. Martin JN, Ganem DE, Osmond DH, et al. Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med 1998; 338(14): 948.
39. Greenblatt RM, Jacobson LP, Levine AM, et al. Human herpesvirus 8 infection and Kaposi's sarcoma among human immunodeficiency virus-infected and -uninfected women. J Infect Dis 2001; 183(7): 1130.
40. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transpl 1990: 53.
41. Palefsky JM, Holly EA, Ralston ML, et al. High incidence of anal high-grade squamous intra-epithelial lesions among HIV-positive and HIV-negative homosexual and bisexual men. Aids 1998; 12(5): 495.
42. Holly EA, Ralston ML, Darragh TM, et al. Prevalence and risk factors for anal squamous intraepithelial lesions in women. J Natl Cancer Inst 2001; 93(11): 843.
43. Palefsky J, Holly E, Ralston M, et al. The effect of highly active antiretroviral therapy on the natural history of anal squamous intraepithelial lesions and anal human papillomavirus infection. J Ac Qimmun Defic Syndr 2001. 2001; 5(28): 422.
44. Frisch M, Biggar RJ, Engels EA, et al. Association of cancer with AIDS-related immunosuppression in adults. Jama 2001; 285(13): 1736.
45. Kolopp-Sarda MN, Renoult E, Gregoire MJ, et al. Increased usage of TCR V-beta8 in kidney transplant recipients with aberrant immune reconstitution and clinical complications. Transplantation 1999; 67(11): 1441.
46. Giovannetti A, Pierdominici M, Mazzetta F, et al. T cell responses to highly active antiretroviral therapy defined by chemokine receptors expression, cytokine production, T cell receptor repertoire and anti-HIV T-lymphocyte activity. Clin Exp Immunol 2001; 124(1): 21.
47. Baluom M FL, Carlson L, Roland ME, et al. A one year evaluation of the interactions between antiviral immunosuppressant medication in HIV+ kidney and liver transplant patients. Presented at the AAPS Annual Meeting and Exposition, Toronto, Ontario, Canada, November 10-14, 2002.